Esophagus, Stomach & Upper GI · Article 24

When Should Fecal Calprotectin Be Used in IBD?

Fecal calprotectin use requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Fecal calprotectin use clinical reference — Related free clinical resource: Practice Review in Gastroenterology.

Fecal calprotectin use: practical clinical approach

This page focuses on Fecal calprotectin use with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Fecal calprotectin use

Clinical takeaway: For Fecal calprotectin use, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer in brief: Fecal calprotectin (FC) is most useful when the clinical question is whether intestinal inflammation is likely to be active. In established ulcerative colitis, the 2025 ACG guideline strongly recommends FC to assess response to therapy, evaluate suspected relapse and monitor maintenance. In Crohn’s disease, the 2025 ACG guideline gives a practical diagnostic range—values above roughly 50-100 micrograms/g increase suspicion for inflammatory disease when distinguishing IBD from non-inflammatory disorders. Interpretation must remain contextual because infection, NSAID exposure and other inflammatory conditions can also raise FC, while isolated proximal small-bowel Crohn’s disease may produce a lower signal than active colitis.

FC is better at inflammation than diagnosis

Calprotectin is released by neutrophils. A low value makes substantial active intestinal inflammation less likely; a high value says inflammation is plausible but does not identify the cause. It should therefore be used to answer a probability question, not to declare ‘Crohn’s disease’ from a stool result.

Diagnosis versus IBS

In a patient with chronic diarrhea and no alarm features, FC can help determine whether an inflammatory work-up is justified. The 2025 Crohn’s guideline notes a practical cut-off range around 50-100 micrograms/g for distinguishing inflammatory from non-inflammatory disease, but laboratory assays and pretest probability matter.

Monitoring treatment response

Falling FC after induction supports biologic response and can reduce reliance on repeated endoscopy in the short term. Persistent elevation despite symptom improvement raises concern for ongoing mucosal inflammation and should prompt reassessment rather than automatic reassurance.

Suspected relapse

In a patient with known IBD who develops diarrhea or urgency, FC can help distinguish inflammatory relapse from IBS overlap, bile acid diarrhea, infection or another non-inflammatory cause. It should often be paired with stool infection testing when clinically indicated.

Do not overreact to a single borderline result

Day-to-day biological variability and assay differences mean borderline values are often best repeated in context. Trends can be more informative than isolated numbers, especially in an otherwise stable patient.

A practical clinical approach

Define whether the question is diagnosis, response, maintenance monitoring or suspected relapse.
Interpret FC alongside symptoms, infection testing and CRP rather than in isolation.
Use low results to avoid unnecessary invasive testing when pretest risk is low.
Use persistently high or rising results to trigger objective reassessment.
When values are borderline and the patient is stable, repeat before making a major treatment change.

Common errors to avoid

Calling any elevated FC ‘IBD’.
Escalating advanced therapy from a single borderline result.
Ignoring enteric infection.
Assuming a low FC completely excludes isolated small-bowel Crohn’s disease.

What should trainees remember?

Fecal calprotectin is a probability and monitoring tool. Its greatest value is reducing the gap between symptoms and objective inflammatory activity.

Frequently asked questions

What FC level suggests inflammation?

No single threshold is universal, but the 2025 ACG Crohn’s guideline gives a practical 50-100 micrograms/g range for distinguishing inflammatory from non-inflammatory disease.

Can FC replace colonoscopy?

Not completely. It can reduce unnecessary procedures and guide timing, but endoscopy remains necessary for important diagnostic and treatment targets.

Can infection raise FC?

Yes.

References

1. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014. ISBN 978-1500855321.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015. ISBN 978-1515078623.

3. Lichtenstein GR, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Updated June 2025.

4. Rubin DT, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Updated June 2025.

5. Turner D, et al. STRIDE-II. Gastroenterology. 2021;160:1570-1583.

← Back to Clinical Questions